Gut Bacteria in CHILDREN with IBS VS. HEALTHY CHILDREN

VERY GOOD ARTICLE THAT DISCUSSES CHILDREN WITH IBS COMPARED WITH HEALTHY CHILDREN.  WHAT DIFFERENCES ARE FOUND IN THE INTESTINES?  RESEARCHERS AND DOCTORS REPORT THEIR FINDINGS.

ARTICLE HIGHLIGHTS 

Gut Microbial Enterotypes and Dietary Patterns

Diet can affect health by modulating gut microbiome composition, and University of Pennsylvania researchers reported that certain microbial enterotype states are associated with long-term dietary patterns (Wu GD et al. Science 2011;334:105-108).

"Senior study author Robert Shulman, MD, professor of pediatrics at Baylor College of Medicine, explained that “this does not necessarily mean that the bacteria cause the pain, but that children with IBS have certain species of bacteria that are less likely to be found in the intestines of healthy children"

Gastroenterology & Endoscopy News - Studies Link Composition of Gut Microbiome to Childhood IBS, Long-term Dietary Patterns

Bloomberg Article - Abbott Rakes It In With Humira Sales

And the winner is ...... HUMIRA!!!  Abbott must really be working their pharmaceutical reps on marketing Humira.  


Abbott Profit Tops Estimates as Humira Drug Sales Climb - Bloomberg

Sorry I've Been MIA

There was a death in my family and i've been out of town and just busy with things.  I will get back to posting blogs very soon.  Thank you for understanding and hope everyone is well.

Translational Research-To Develop Better Autoimmune Illness Treatments.....FASTER!

Ahhahaha LOVE THIS!
This is not a usual article...  I laugh because reading this makes me happy! 
I'm glad I'm not the only impatient, tapping the foot-anxious human (yes, I'm on the edge of my seat awaiting the good news) for researchers, scientists, mega-motivated lab chemists (those white coat chemical mixing, studying, observing, developing & discovering the good & hopefully safe therapy that will save/improve lives- I love you people.. What would we do without you/them?).  So many people agree with me, in respects to finding effective treatments that get down to the root causes for these diseases; ones that are placing the blame on a dysfunctioning immune system (which in my opinion, the term "autoimmune disease" is just a clinical label for a condition that medical professionals don't know what is making the body respond in the dysfunctional way that makes the patient experience varying degrees of ill.  

Well, I think I'm liking the sound of this research approach - "Translational Research"  

BRI associate director Jane Buckner, MD & Per Falk, senior vice president, Biopharmaceuticals Research Unit, Novo Nordisk. -       Are you driven to finally get to the bottom of what's causing these diseases?  YES??!!  Awesome!    Can you crack the whip please?  Millions will thank you!
  

ARTICLE HIGHLIGHTS

“Translational research" describes a research approach that seeks to move discoveries made in laboratory, clinical or population studies more quickly into clinical care. In this specific agreement, BRI scientists and Novo Nordisk researchers at the company’s Seattle research center will work together to study samples and data registered in BRI’s biobank of patients with these diseases (IBD, Lupus, Rheumatoid Arthritis), as well people with no history of autoimmune disorders. "

"The agreement establishes how Novo Nordisk and BRI research scientists and BRI clinicians will collaboratively develop studies to better understand changes in the immune systems of patients living... autoimmune diseases...Intent is to develop better therapies and improve how these treatments are used." 

Partnership May Speed Research for IBD, Other Diseases

SEATTLE—Benaroya Research Institute at Virginia Mason (BRI), a non-profit biomedical research institute in Seattle, Wash., and Novo Nordisk, a global health care company headquartered in Denmark, recently announced a three-year collaborative agreement to potentially speed-up translational research of the diagnosis and treatment of rheumatoid arthritis, inflammatory bowel disease and lupus.
The agreement establishes how Novo Nordisk and BRI research scientists and BRI clinicians will collaboratively develop studies to better understand changes in the immune systems of patients living with these autoimmune diseases. The intent is to develop better therapies and improve how these treatments are used.
Autoimmune diseases happen when the immune system, designed to protect the body, attacks it instead.
“Translational research" describes a research approach that seeks to move discoveries made in laboratory, clinical or population studies more quickly into clinical care. In this specific agreement, BRI scientists and Novo Nordisk researchers at the company’s Seattle research center will work together to study samples and data registered in BRI’s biobank of patients with these diseases, as well people with no history of autoimmune disorders. The personal information of these patients will not be disclosed.
“This is the first time we have established a collaborative agreement like this and we’re pleased to be working so closely with Novo Nordisk to integrate scientific discovery, the development of diagnostic and treatment solutions and their clinical application," said BRI associate director Jane Buckner, MD, a practicing rheumatologist and leader of the Kenneth R. Wilske Center for Translational Research at Virginia Mason. “We anticipate that this will accelerate as never before our ability to better understand, diagnose and treat these illnesses."

“Improving patient care through innovation is at the heart of our company culture and this agreement represents one way that we can work together with the larger health care research community to achieve this objective," said Per Falk, senior vice president, Biopharmaceuticals Research Unit, Novo Nordisk. “We’re pleased to be working closely with the Seattle scientific community, which is sharing its best and brightest with us in an effort to bring new medicines for patients."
In the United States alone as many as 1.5 million people suffer from rheumatoid arthritis or inflammatory bowel disease, and more than one-half million people suffer from lupus.
Benaroya Research Institute at Virginia Mason maintains one of the world’s most robust biobanks for the study of autoimmune disorders, with samples and patient histories dating back to 2000. A biobank, or biorepository, consists of the fresh and frozen blood and serum samples and medical and demographic information collected from people with a specific disease or condition. BRI actively maintains biorepositories for eleven different autoimmune disorders and immune mediated diseases including multiple sclerosis, Type 1 diabetes, lupus, rheumatoid arthritis, scleroderma, inflammatory bowel disease, allergy, asthma, lung disease and transplant recipients. BRI also maintains a registry of healthy people for comparison purposes.
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 89 years experience. Benaroya Research Institute at Virginia Mason (BRI), founded in 1956, is an international leader in immune system and autoimmune disease research, translating discoveries to real-life applications

Chronic Disease Management Prog. Expands Online

Article -->




Successful chronic disease management program to be expanded online - Community News Blog